{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:47:46Z","timestamp":1788266866040,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.mayocp.2025.06.001","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T15:17:09Z","timestamp":1754407029000},"page":"1621-1631","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Year in Review: Selection of Best Papers in Gastroenterology and Hepatology 2024"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6472-7514","authenticated-orcid":false,"given":"Michael","family":"Camilleri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan S.","family":"Dellon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mayocp.2025.06.001_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/j.gastro.2022.09.041","article-title":"Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial","volume":"164","author":"Laine","year":"2023","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.mayocp.2025.06.001_bib2","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.cgh.2024.05.004","article-title":"Vonoprazan is efficacious for treatment of heartburn in non-erosive reflux disease: a randomized trial","volume":"22","author":"Laine","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.mayocp.2025.06.001_bib3","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/apt.17728","article-title":"Randomised clinical trial: efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease","volume":"58","author":"Fass","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.mayocp.2025.06.001_bib4","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.cgh.2024.10.016","article-title":"Daily or twice daily treatment with topical steroids results in similar responses in eosinophilic esophagitis","volume":"23","author":"Reed","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.mayocp.2025.06.001_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13899","article-title":"Dupilumab: mechanism of action, clinical, and translational science","volume":"17","author":"McCann","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"12","key":"10.1016\/j.mayocp.2025.06.001_bib6","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.14309\/ajg.0000000000002924","article-title":"Dupilumab improves health-related quality of life and a range of symptoms in patients with eosinophilic esophagitis","volume":"119","author":"Spergel","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"24","key":"10.1016\/j.mayocp.2025.06.001_bib7","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa2312282","article-title":"Dupilumab for eosinophilic esophagitis in patients 1 to 11 years of age","volume":"390","author":"Chehade","year":"2024","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.mayocp.2025.06.001_bib8","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2313318","article-title":"Eosinophil depletion with benralizumab for eosinophilic esophagitis","volume":"390","author":"Rothenberg","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2025.06.001_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.gastro.2023.09.004","article-title":"Ascending to new heights for novel therapeutics for eosinophilic esophagitis","volume":"166","author":"Hirano","year":"2024","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.mayocp.2025.06.001_bib10","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jaci.2024.08.023","article-title":"One-food versus 4-food elimination diet for pediatric eosinophilic esophagitis: a multisite randomized trial","volume":"155","author":"Kliewer","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.mayocp.2025.06.001_bib11","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S2468-1253(23)00012-2","article-title":"One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial","volume":"8","author":"Kliewer","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10414","key":"10.1016\/j.mayocp.2025.06.001_bib12","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)01523-4","article-title":"Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Ford","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.mayocp.2025.06.001_bib13","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMoa2409712","article-title":"Inebilizumab for treatment of IgG4-related disease","volume":"392","author":"Stone","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.mayocp.2025.06.001_bib14","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1056\/NEJMra2309041","article-title":"Pancreatic cysts","volume":"391","author":"Gonda","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2025.06.001_bib15","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.cgh.2024.07.048","article-title":"Multimodal pancreatic cancer detection using methylated DNA biomarkers in pancreatic juice and plasma CA 19-9: a prospective multicenter study","volume":"23","author":"Engels","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.mayocp.2025.06.001_bib16","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","article-title":"Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for inflammatory bowel disease: two randomized phase 3 trials (LIBERTY)","volume":"167","author":"Hanauer","year":"2024","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.mayocp.2025.06.001_bib17","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1136\/gutjnl-2024-332504","article-title":"Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD","volume":"74","author":"Bamias","year":"2025","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.mayocp.2025.06.001_bib18","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa2314076","article-title":"Phase 2 trial of anti-TL1A monoclonal antibody tulisokibart for ulcerative colitis","volume":"391","author":"Sands","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.mayocp.2025.06.001_bib19","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for ulcerative colitis: two randomized clinical trials","volume":"332","author":"Louis","year":"2024","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.mayocp.2025.06.001_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab versus ustekinumab for moderate-to-severe Crohn's disease","volume":"391","author":"Peyrin-Biroulet","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2025.06.001_bib21","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1056\/NEJMoa2312302","article-title":"Neutralizing autoantibodies against interleukin-10 in inflammatory bowel disease","volume":"391","author":"Griffin","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2025.06.001_bib22","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.gie.2024.07.027","article-title":"Colonoscopy quality measures and adherence to follow-up guidelines among endoscopists participating in a U.S. endoscopy registry","volume":"101","author":"Shapiro","year":"2025","journal-title":"Gastrointestinal Endosc"},{"issue":"12","key":"10.1016\/j.mayocp.2025.06.001_bib23","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.7326\/ANNALS-24-00981","article-title":"Artificial intelligence\u2013assisted colonoscopy for polyp detection: a systematic review and meta-analysis","volume":"177","author":"Soleymanjahi","year":"2024","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.mayocp.2025.06.001_bib24","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJMoa2310336","article-title":"Next-generation multitarget stool DNA test for colorectal cancer screening","volume":"390","author":"Imperiale","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.mayocp.2025.06.001_bib25","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1136\/gutjnl-2014-308075","article-title":"Molecular markers for colorectal cancer screening","volume":"64","author":"Dickinson","year":"2015","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.mayocp.2025.06.001_bib26","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000360","article-title":"Multitarget stool RNA test for noninvasive detection of colorectal neoplasias in a multicenter, prospective, and retrospective cohort","volume":"12","author":"Barnell","year":"2021","journal-title":"Clin Transl Gastroenterol"},{"issue":"3","key":"10.1016\/j.mayocp.2025.06.001_bib27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1001\/jama.2024.9289","article-title":"Lowering fecal immunochemical test positivity threshold vs multitarget stool RNA testing for colorectal cancer screening","volume":"332","author":"Niedermeier","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.mayocp.2025.06.001_bib28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1001\/jamainternmed.2024.6149","article-title":"Next-generation multitarget stool DNA vs fecal immunochemical test in colorectal cancer screening","volume":"185","author":"Seum","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.mayocp.2025.06.001_bib29","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1053\/j.gastro.2024.03.011","article-title":"Comparative effectiveness and cost-effectiveness of colorectal cancer screening with blood-based biomarkers (liquid biopsy) vs fecal tests or colonoscopy","volume":"167","author":"Ladabaum","year":"2024","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.mayocp.2025.06.001_bib30","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa2304714","article-title":"A cell-free DNA blood-based test for colorectal cancer screening","volume":"390","author":"Chung","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.mayocp.2025.06.001_bib31","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer","volume":"391","author":"Thierry","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.mayocp.2025.06.001_bib32","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair\u2013deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2025.06.001_bib33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.mayocp.2025.06.001_bib34","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","article-title":"Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"19","author":"Stine","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.mayocp.2025.06.001_bib35","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s00018-024-05507-6","article-title":"GLP-1 and GIP agonism has no direct actions in human hepatocytes or hepatic stellate cells","volume":"81","author":"da Silva Lima","year":"2024","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"10.1016\/j.mayocp.2025.06.001_bib36","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/gutjnl-2024-334023","article-title":"Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists","volume":"74","author":"Targher","year":"2025","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.mayocp.2025.06.001_bib37","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.mayocp.2025.06.001_bib38","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2025.06.001_bib39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2021","journal-title":"Metabolites"},{"issue":"6","key":"10.1016\/j.mayocp.2025.06.001_bib40","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.mayocp.2025.06.001_bib41","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction\u2013associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2025.06.001_bib42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2025.06.001_bib43","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-G\u00f3mez","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.mayocp.2025.06.001_bib44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study","volume":"82","author":"Harrison","year":"2025","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.mayocp.2025.06.001_bib45","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction\u2013associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.mayocp.2025.06.001_bib46","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1001\/jamainternmed.2024.4661","article-title":"GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction\u2013associated steatotic liver disease","volume":"184","author":"Kanwal","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"10165","key":"10.1016\/j.mayocp.2025.06.001_bib47","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mayocp.2025.06.001_bib48","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cgh.2023.04.012","article-title":"Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study","volume":"22","author":"Abdelmalek","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.mayocp.2025.06.001_bib49","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cgh.2023.04.011","article-title":"Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized phase 2b study","volume":"22","author":"Loomba","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.mayocp.2025.06.001_bib50","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cmet.2019.01.004","article-title":"A dozen years of discovery: insights into the physiology and pharmacology of FGF21","volume":"29","author":"Kliewer","year":"2019","journal-title":"Cell Metab"},{"issue":"10","key":"10.1016\/j.mayocp.2025.06.001_bib51","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.3390\/biomedicines12102328","article-title":"Comparative analysis of resmetirom vs. FGF21 analogs vs. GLP-1 agonists in MASLD and MASH: network meta-analysis of clinical trials","volume":"12","author":"Ayesh","year":"2024","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.mayocp.2025.06.001_bib52","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.mayocp.2025.06.001_bib53","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619625003106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619625003106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T15:44:55Z","timestamp":1763307895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619625003106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0025619625003106"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2025.06.001","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Year in Review: Selection of Best Papers in Gastroenterology and Hepatology 2024","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2025.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}